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Abstract: BACKGROUND AND AIMS Ulcerative colitis (UC) patients have a greater risk of developing
colorectal cancer through inflammation-dysplasia-carcinoma sequence of transformation. The histopatho-
logical diagnosis of dysplasia is therefore of critical clinical relevance, but dysplasia may be difficult to
distinguish from inflammatory changes. METHODS A proteomic pilot study on 5 UC colorectal dys-
plastic patients highlighted proteins differentially distributed between paired dysplastic, inflammatory
and normal tissues. The best candidate marker was selected and immunohistochemistry confirmation
was performed on AOM/DSS mouse model lesions, 37 UC dysplasia, 14 UC cancers, 23 longstanding
UC, 35 sporadic conventional adenomas, 57 sporadic serrated lesions and 82 sporadic colorectal cancers.
RESULTS Differential proteomics found 11 proteins significantly more abundant in dysplasia compared
to inflammation, including Solute carrier family 12 member 2 (SLC12A2) which was confidently identi-
fied with 8 specific peptides and was below the limit of quantitation in both inflammatory and normal
colon. SLC12A2 immunohistochemical analysis confirmed the discrimination of preneoplastic and neo-
plastic lesions from inflammatory lesions in mice, UC and in sporadic contexts. A specific SLC12A2
staining pattern termed ”loss of gradient” reached 89% sensitivity, 95% specificity and 92% accuracy
for UC-dysplasia diagnosis together with an inter-observer agreement of 95.24% (multirater ฀free of 0.90;
IC95%: 0.78 - 1.00). Such discrimination could not be obtained by Ki67 staining. This specific pattern
was also associated with sporadic colorectal adenomas and cancers. CONCLUSIONS We found a specific
SLC12A2 immunohistochemical staining pattern in precancerous and cancerous colonic UC-lesions which
could be helpful for diagnosing dysplasia and cancer in UC and non-UC patients.
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Background and Aims: Ulcerative colitis (UC) patients have a greater risk of developing colorectal 
cancer through inflammation-dysplasia-carcinoma sequence of transformation. The histopathological 
diagnosis of dysplasia is therefore of critical clinical relevance, but dysplasia may be difficult to 
distinguish from inflammatory changes.  
Methods: A proteomic pilot study on 5 UC colorectal dysplastic patients highlighted proteins 
differentially distributed between paired dysplastic, inflammatory and normal tissues. The best 
candidate marker was selected and immunohistochemistry confirmation was performed on AOM/DSS 
mouse model lesions, 37 UC dysplasia, 14 UC cancers, 23 longstanding UC, 35 sporadic conventional 
adenomas, 57 sporadic serrated lesions and 82 sporadic colorectal cancers.  
Results: Differential proteomics found 11 proteins significantly more abundant in dysplasia compared 
to inflammation, including Solute carrier family 12 member 2 (SLC12A2) which was confidently 
identified with 8 specific peptides and was below the limit of quantitation in both inflammatory and 
normal colon. SLC12A2 immunohistochemical analysis confirmed the discrimination of preneoplastic 
and neoplastic lesions from inflammatory lesions in mice, UC and in sporadic contexts. A specific 
SLC12A2 staining pattern termed “loss of gradient” reached 89% sensitivity, 95% specificity and 
92% accuracy for UC-dysplasia diagnosis together with an inter-observer agreement of 95.24% 
(multirater κfree of 0.90; IC95%: 0.78 – 1.00). Such discrimination could not be obtained by Ki67 
staining. This specific pattern was also associated with sporadic colorectal adenomas and cancers.  
Conclusions: We found a specific SLC12A2 immunohistochemical staining pattern in precancerous 
and cancerous colonic UC-lesions which could be helpful for diagnosing dysplasia and cancer in UC 
and non-UC patients.   
 














































































































Chronic inflammation is known to be linked with cancer development, like in inflammatory bowel 
diseases (IBD). Patients suffering from IBD, such as ulcerative colitis (UC) and Crohn’s disease 
(CD), are at risk of developing colorectal cancer (CRC) in areas affected by chronic inflammation, 
namely colitis-associated cancer (CAC).1 In the last decades, the risk of CAC in UC patients has 
decreased, mainly due to a better control of chronic inflammation, and to more effective surveillance 
programs including high resolution endoscopy and chromoendoscopy.2,3 Despite these advances, CAC 
remains a clinical problem. IBD patients show a 5% cumulative risk of CAC after more than 20 years 
of disease duration, and this risk is even higher with additional presence of extensive disease, primary 
sclerosing cholangitis and if the disease occurred at a young age.4,5 A recent meta-analysis concluded 
that suffering from UC increases the risk of colorectal cancer by 2.4-fold compared to the general 
population.6 
CAC develops following the sequence of transformation “inflammation-dysplasia-adenocarcinoma”.7 
Chronic inflammation leads to oxidative stress-induced DNA damages in colonic epithelium, which 
induce the activation of pro-carcinogenic and silencing of tumour suppressor genes.8,9 All these events 
lead to epithelial dysplasia.10 Most of the key regulator genes (e.g. TP53 and APC) involved in the 
CRC development are also found in the inflammation-associated dysplasia and CAC development, 
but their sequence of mutation, their frequency and occurrences differ in CAC from CRC. 9,11 
Identification of colonic dysplasia is essential for IBD patient surveillance. However, before 2015, 
endoscopic classification of dysplasia was confusing. This led to the establishment of the SCENIC 
International Consensus Statement on surveillance and management of dysplasia in IBD.12 To provide 
recommendations for diagnosis and surveillance, SCENIC standardized the terminology of 
endoscopic dysplastic lesions, adapted from the Paris classification.13 However, ongoing histological 
inflammation, which is often observed even in patients reporting clinical remission, makes the 
histopathological confirmation of dysplasia particularly difficult. Indeed, regenerative epithelium 
found in inflammatory areas shares features with dysplasia, including nuclear enlargement, 
hyperchromasia, stratification and an increased number of mitoses, leading to a diagnosis of indefinite 
for dysplasia.14   
The aim of our study was to highlight potential protein markers able to discriminate early dysplasia 
from inflammation and normal colon. We therefore performed a pilot proteomic study using laser-
capture microdissection (LCM) and 2D nano-UPLC-MS/MS on colonic low-grade dysplasia in UC. 
The best biomarker candidate was confirmed by immunohistochemistry (IHC) on 
Azoxymethane/Dextran sulfate sodium (AOM/DSS) colon tissues and on an independent panel of 














































































































Patient inclusions, clinical information and tissues samples 
Human formalin-fixed paraffin-embedded (FFPE) colorectal tissues were obtained from several 
biobanks hospitals after approvals of their ethical reviewing boards: University Hospital CHU Liège 
(ref: 2015-144), the Centre Hospitalier Régional de la Citadelle CHR Liège (ref: 16/14/802), Centre 
Hospitalier Chrétien CHC Liège (ref: FD/bl/1578 – B412201628406), University Hospital of Zurich 
(ref: KEK ZH 2018-02193) and the Centre Hospitalier Universitaire Vaudois (ref: CER-VD 2019-
00082).  
For the proteomic study, we retrospectively (from 2008 to 2015) selected 98 UC patients with 
confirmed colorectal dysplasia developed in inflammatory areas (dysplasia associated to 
inflammation, DAI) at CHU Liège. Exclusion criteria were: previous or concomitant cancer and 
inherited disorders increasing the risk of colorectal cancer (Lynch syndrome and familial 
adenomatous polyposis). To confirm the dysplastic, inflamed or normal aspect of the available tissues, 
haematoxylin and eosin (H&E) stained sections were reviewed by an expert gastrointestinal (GI) 
pathologist (N.B.). This review was based on the European Crohn’s and Colitis Organisation (ECCO) 
guidelines for histopathology in IBD and the Surveillance for Colorectal Endoscopic Neoplasia 
detection and management in inflammatory bowel disease patient : International Consensus 
recommendations (SCENIC) criteria.12,15 Due to the limited amount of material available, the 
requirements of the downstream technical hints of sample preparation for differential proteomic 
analysis, we finally selected 5 UC patients with polypoid low-grade dysplasia associated to UC (UC-
DAI) also providing available tissues with either  inflammation (UC-I) or without any alteration and  
defined as normal (UC-N) (Table 1). These 3 tissue types originating from the same 5 patients were 
therefore qualified as paired samples.  
For the IHC studies, we included 74 UC patients. Table 1 details the clinical information of these 
patients showing different lesions types : 28 UC-DAI cases (including the five cases studied by 
proteomics) with matched UC-I (n=21) and/or UC-N (n=9) tissues when available; 9 UC with 
dysplasia developed on inflammation-free mucosa (UC-DSp) and matched normal paired tissues UC-
N (n=6); 14 colitis associated colorectal cancer tissues (UC-CAC) with paired inflammatory tissues 
UC-I (n=8) and/or normal UC-N (n=11) when available; 23 longstanding UC patients (patients with ≥ 
10 years disease duration who did not developed dysplasia, all previous colonoscopies or colectomies 
where negative for dysplasia and cancer) 16,17 with UC-I (n=23) and paired UC-N (n=15) tissues.  
Table 2 summarizes the clinical information of 18 non-IBD controls (normal margin of diverticulitis 
specimen) and 174 patients with sporadic precancerous or cancerous lesions:  conventional low-grade 
adenomas (LGA) (n=19), high-grade adenomas (HGA) (n=16),  sessile serrated adenomas/polyps 
(SSA/P) (n=19), traditional serrated adenomas (TSA) (n=19), hyperplastic polyps (HPP) (n=19), and 
sporadic colorectal cancers pT1 (n=19), pT2 (n=22), pT3 (n=22) and pT4 (n=19), all reviewed by our 
GI pathologist (N.B.) according to standardized guidelines and the American Joint Committee on 
Cancer (AJCC) Cancer Staging Manual.18 When accessible, we characterized the normal tissues 
directly adjacent to the cancerous lesions (the normal tissue surrounding the cancer on the same 
specimen section) with respectively pT1-adjacent (n=12), pT2-adjacent (n=16), pT3-adjacent (n=9) 
and pT4-adjacent (n=9) and the normal paired tissues taken at the surgical margin : pT1-margin (n=8), 
pT2-margin (n=10), pT3-margin (n=12) and pT4-margin (n=8).  













































































































Colon tissues of AOM/DSS19 or DSS mice were obtained thanks to a collaboration with Dr. Oury’s 
laboratory, GIGA-Cardiovascular Sciences, ULiège (C.O., L.S. and O.W.). The mouse study was 
approved by the Committee on the Ethics of Animal Experiments of the University of Liège (permit 
no.1220).   
In the AOM/DSS model, 5-week old C57Bl/6J mice (JAXTM Mice Strain) (Charles River, France) 
were injected once intraperitoneally (12 mg/kg) with AOM carcinogen (Sigma-Aldrich, Saint Louis, 
USA) diluted in phosphate buffer saline (PBS) before receiving three cycles of DSS (2%) (45 kDa; 
TdB Consultancy, Uppsala, Sweden) via drinking water for 5 days, followed by 16 days of regular 
water. Mice were euthanized at day 15, 29, 34, 50, 55, 65, 70, 80 and 120.  In the chronic 
inflammation model, mice were treated with DSS (3%) for 5 days followed by 21 days of regular 
water.20 The acute inflammation model was induced by treatment with DSS (5%) for 6 days. Control 
mice only received PBS and were euthanized at day 90. A total of 81 mice were studied. Colons were 
collected and FFPE as previously described.21 The GI pathologist (N.B.) reviewed each H&E stained 
sections to identify all lesions such as inflammation, dysplasia or adenocarcinoma with 
characterisation of stage and morphology (see supplementary Table 1 for details). The number of 
tissues analysed per lesion types are as follows: low-grade dysplasia (LGD) (n=51) and paired 
inflammatory tissues (I-LGD), high-grade dysplasia (HGD) (n=35) and paired inflammatory tissues 
(I-HGD), adenocarcinoma (ADC) (n=38) and paired inflammatory tissues (I-ADC), inflammatory 
tissues (I) (n=20) and normal tissues (PBS) (n=12). 
Label free proteomic study  
Sample preparation and proteomics by LC-MS/MS 
Before the proteomic analysis, we performed laser capture microdissection for epithelial cell 
enrichment. We collected a total of 5000 epithelial cells per tissue type on 5 µm tissue sections using 
a Leica LMD 7000 (Leica Microsystems, Wetzlar, Germany) according to the manufacturer 
instructions (see Supplementary data for details). 
The 15 samples were all processed using a specific antigen retrieval and double trypsin digestion 
protocol previously described.22  
Peptide digests separation was achieved by reverse-phase liquid chromatography using a 2 
dimensions (2D) ultra-performance liquid chromatography (UPLC) on a nanoAcquity instrument 
(Waters, Milford, USA) as detailed previously.22 A 2D nano-UPLC coupled to a Thermo Scientific Q 
Exactive Plus Hybrid Quadrupole-orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, 
USA) equipped with a nanospray ESI source operated in positive mode was used as detailed  in 
Supplementary data.  
Protein identifications and differential analysis  
The analysis of the raw spectra was performed using MaxQuant 1.5.2.8. for the protein identifications 
and Label free quantification (LFQ) (see Supplementary data for search parameters).23 Raw data files 
have been deposited to the ProteomeXchange Consortium via the PRIDE24 partner repository 
(http://proteomecentral.proteomexchange.org, identifier PXD018679). 
We used Perseus 1.5.5.0 for differential analysis with Log2 transformed LFQ values.25 We applied a 
one-way ANOVA test to compare the three groups and a paired Student t test to compare groups two 













































































































belonging to on group when a LFQ value was available in 5 replicates out of 5 for one group and no 
LFQ value was available in 5 out of 5 replicates for the other group; meaning that the protein was 
significantly identified but below the limit of quantification of the technique in this specific 
experimental and instrumental setup. 
Immunohistochemistry experiments 
IHC sample preparation 
FFPE tissue sections were treated as previously described.26 Tissue sections were incubated 1h at 
room temperature with primary antibodies: polyclonal Anti-SLC12A2 antibody HPA020130 (Sigma-
Aldrich, Saint Louis USA) used at 1/2000 for human tissues and polyclonal Anti-NKCC1 antibody 
ab59791 (Abcam, Cambridge, United Kingdom) used at 1/1000 for mouse tissues; Ki67 antibody 
[SP6] (Abcam, Cambridge, United Kingdom) at 1/200 dilution. Absence of primary antibody was 
used as negative control conditions. 
IHC characterisation  
Three independent scorers (A.-M. M., C. M. and M.-A. M.) not trained in pathology and without prior 
knowledge of clinical data, evaluated the IHC sections. SLC12A2 IHC characterization was 
established according to two parameters. First, the staining pattern was qualified as “gradient” or “loss 
of gradient”. The gradient was defined as a decreasing staining intensity from the base bottom of the 
crypts to the surface epithelium. The loss of gradient was established when the gradient could not be 
observed (showing either heterogeneous staining or homogenous staining along the crypt and surface 
epithelium) (see Figures 2C.1, 2C.2 and 2C.5 for gradient pattern, and 2C.4 and 2C.6 for the loss of 
gradient pattern illustrations). In case of conflicting results between the scorers, the final consensus 
after discussion or the minimum agreement of 2 out of the 3 scorers was taken as final results. 
Second, a semi-quantitative evaluation of the staining intensity was made according to the estimation 
of the percentage of the stained cells and the signal intensity in these positive cells ranging from 0 to 
4: 0=no staining, 1=weak, 2=medium, 3=strong, 4=very strong. Practically, due to the existence of a 
gradient between surface and crypt epithelium in some samples, the staining intensity score was 
obtained by the averaged value of the scores of the surface epithelium and the base bottom of the 
crypts. The final staining score of the tissue lesion was obtained based on the mean of the 3 scorers. 
The Ki67 IHC was performed on some UC-DAI cases with available tissue (n=14). Positive nuclei 
were counted. The Ki67 IHC sections were scanned using Hamamatsu Photonics K.K. (Hamamatsu 
Photonics Europe GmbH, Herrsching, Germany) (magnification 40X) and uploaded on QuPath 0.1.2 
(Queen’s University, Belfast, Northern Ireland) for cellular count. Counts established on four fields 
for each lesion or tissue type were analysed and averaged.  
IHC data analysis 
We used GraphPad Prism 7.00 (GraphPad Software, La Jolla, USA) for statistical analyses of IHC 
results. Kruskal-Wallis test was applied to compare SLC12A2 staining intensity score in all groups. 
Wilcoxon paired or Mann-Whitney unpaired tests were applied when appropriated to compare groups 
2 by 2.  
We applied Chi-squared test to compare all groups and Fisher’s exact test for 2 by 2 comparisons for 













































































































The one-way ANOVA test was used to compare the percentage of Ki67 positive cells in all groups. 
Tukey’s post-hoc test was applied to compare groups 2 by 2. Pearson r correlation test was applied to 
analyse the correlation between SLC12A2 staining intensity score and the percentage of Ki67 positive 
cells. Chi-square or Fisher’s exact tests were applied when appropriate to test the association of 
SLC12A2 staining pattern with different Ki67 staining categories as previously reported (based on 













































































































Staining pattern diagnosis power evaluation 
We investigated the discrimination of precancerous and cancerous tissues from normal and 
inflammatory ones using the SLC12A2 staining pattern with the loss of gradient as discriminating 
positive parameter. We evaluated the number of patients correctly classified evaluating the sensitivity, 
specificity and accuracy in the UC and the sporadic contexts. Inter-observer overall agreement (OA) 
was assessed by the free-marginal multirater kappa (multirater κfree) based on the results if the three 















































































































A total of 1070 proteins were identified and 982 were quantified through all samples. Among these, 
438 proteins were quantified in minimum 3 out of 5 replicates in at least one group. When comparing 
UC-DAI and UC-I, 11 proteins were significantly differentially distributed and all of them were more 
abundant in dysplasia, with 6 of which were found below the limit of quantitation in UC-I sample and 
termed “UC-DAI only” (Table 3). When comparing UC-DAI and UC-N, 14 proteins were 
significantly differentially distributed: one was higher in UC-N, 10 were more abundant in UC-DAI 
and 3 were only quantified in UC-DAI (UC-DAI only) (Table 3). When comparing UC-I and UC-N, 
18 proteins were significantly differentially distributed, 10 were more abundant in UC-I, 7 were 
higher in UC-N and 1 was below the limit of quantification in UC-I and termed “UC-N only” (see 
Table 3). We selected Solute carrier family 12 member 2 (SLC12A2) for further confirmations as it 
was the only protein found as “UC-DAI only” in both UC-DAI versus UC-I and UC-DAI versus UC-
N comparisons. SLC12A2 was therefore the best candidate for discrimination of UC-DAI from UC-I 
and UC-N. SLC12A2 was confidently identified with 8 peptides, all of them were unique to this 
protein and enabled a sequence coverage of 11.3%. No other protein of the same family with similar 
sequence and with unique peptide showed significant results in the differential analyses performed. 
Immunohistochemistry confirmation 
In both mouse and human colorectal tissues, SLC12A2 staining was only observed in epithelial cells 
and not in the extracellular matrix or in the lamina propria. The staining was largely diffuse in the 
cytoplasm and also positive in the membrane and in the nucleus. 
SLC12A2 IHC staining discriminates dysplasia and adenocarcinoma from inflammation in AOM/DSS 
mice 
Staining pattern frequency was differentially distributed across colonic tissue types, with the specific 
loss of gradient pattern being associated to dysplasia and cancer when compared to their surrounding 
inflammatory tissues or to normal control tissues (p ≤ 0.0001). This was also the case when 
comparing dysplasia and cancer to inflammatory colonic tissues (p = 0.0028, < 0.0001 and 0.0010, for 
LGD, HGD and ADC respectively) (Figure 1A). Moreover, precancerous and cancerous lesions 
showed a significant higher staining intensity score than their surrounding inflamed tissues (LGD 
versus I-LGD, HGD versus I-HGD and ADC versus I-ADC, p < 0.0001 each). This was also observed 
when comparing LGD, HGD or ADC to inflammatory colonic tissues (p < 0.0001 each) or controls (p 
= 0.0017, 0.0001 and < 0.0001 for LGD, HGD and ADC respectively) (Figure 1B). 
SLC12A2 IHC staining discriminates UC-dysplasia and cancer from inflammation and normal tissues  
Representative pictures of SLC12A2 IHC distributions are presented for UC-N, UC-I and UC-DAI 
(Figures 2C.1, 2C.2 and 2C.3 respectively). For UC-DAI patients, SLC12A2 staining pattern 
frequency was differentially distributed across colonic tissue types, with the loss of gradient pattern 
being associated to UC-DAI when compared to UC-I and UC-N (p < 0.0001 and = 0.0003). SLC12A2 
staining intensity showed a significant differential distribution with UC-DAI > UC-I (p = 0.0063) and 
with UC-DAI > UC-N (p = 0.0156) (Figure 2B). SLC12A2 did not discriminate UC-I from UC-N 













































































































For UC-DSp patients, SLC12A2 staining pattern frequency was also differentially distributed across 
colonic tissue types: the loss of gradient was associated to UC-DSp when compared to UC-N (p = 
0.0002) (Figure 3A) and Figures 3C.1 and 3C.2 for representative pictures. However, SLC12A2 
staining intensity score in dysplasia showed no difference to normal tissues (Figure 3B). 
SLC12A2 was also able to discriminate UC colitis-associated cancers from other colonic tissues, as its 
staining pattern frequency was differentially distributed across the tissues, with the loss of gradient 
being associated to UC-CAC compared to UC-I and UC-N (p < 0.0001 each) (Figure 4A). For 
SLC12A2 staining intensity score parameter, no difference between UC-CAC and the other tissues 
could be observed (Figure 4B) and Figures 4C.1, 4C.2 and 4C.3 for representative pictures. Moreover, 
no statistical difference in staining pattern or intensity score was obtained between UC-I and UC-N. 
As the SLC12A2 loss of gradient pattern seemed to be specific of colorectal dysplasia and cancer in 
UC patients, we tested this pattern in inflamed and normal colon from longstanding UC patients. No 
significant difference in SLC12A2 staining pattern frequency distribution could be observed between 
longstanding UC-I and UC-N; neither when comparing frequency distribution of these tissues to 
inflammatory or normal colonic tissues originating from UC-DAI, DSp or CAC patients (Figure 5A) 
and Figure 5B.1 and 5B.2 for representative pictures. 
SLC12A2, but not Ki67 is able to discriminate UC-dysplasia from inflammation 
Ki67 immunohistochemical staining did not discriminate dysplasia from inflamed and normal colonic 
tissues originating from the same patients, as a progressive increase in number of positive cells could 
be observed from UC-N to UC-DAI, but without reaching significance (p = 0.8600 for UC-DAI 
versus UC-I, p = 0.2434 for UC-DAI versus UC-N and p = 0.5020 for UC-I versus UC-N, see 
supplementary Table 2 for IHC data). 
No significant association could be observed between the percentages of Ki67 positive cells 
aggregated by categories of percentages or percentiles and the SLC12A2 staining pattern. Moreover, 
no significant correlation between the percentage of Ki67 positive cells and SLC12A2 staining 
intensity score could be obtained (p = 0.5685). 
SLC12A2 IHC staining discriminates colorectal precancerous and cancerous non-UC lesions from 
normal tissues  
Except SSA/P, all non-IBD precancerous and cancerous colorectal lesions showed more frequently 
the SLC12A2 loss of gradient pattern than the normal colonic tissues (see Supplementary Figures 1A 
and 1C). SLC12A2 staining intensity score was significantly higher in conventional colorectal LGA 
and HGA compared to normal colonic tissues and colorectal serrated lesions (Supplementary Figures 
1B and 1C). Neither the pattern nor the intensity score was able to discriminate LGA from HGA 
(Supplementary Figure 1B and 1C) and Supplementary Figures 1D.1 to 1D.9 for representative 
pictures. 
In non-IBD cancerous colorectal lesions, the loss of gradient was significantly more frequent in 
cancerous than in normal colonic tissues (adjacent or taken at surgical margin) (Supplementary Figure 
2A). The staining intensity scores were significantly higher in cancer than in the normal colonic 
tissues (adjacent or taken at surgical margin) (Supplementary Figure 2B).  Despite a trend for increase 
between normal colonic tissues taken at the surgical margin and adjacent to the tumour, no statistical 














































































































SLC12A2 staining pattern as criteria for the discrimination of precancerous and cancerous colorectal 
lesions 
The inter-observer agreement results for SLC12A2 staining pattern assessment between the 3 scorers 
can be found in Table 4, which summarises the overall agreement (OA), the multirater κfree and the 
95% confidence interval (IC) results. For UC-DAI patients, the OA reached 93.10% with multirater 
κfree of 0.86 (IC95%: 0.76 – 0.97) and for UC-DAI lesions, OA reached 95.24% with multirater κfree 
of 0.90 (IC95%: 0.78 – 1.00). 
Table 5 summarises the percentages of sensitivity, specificity and accuracy obtained for each analysis. 
The specific staining pattern taken as criteria was able to discriminate tissue types with at least 83% of 
sensitivity, 83% of specificity and 86% accuracy. The discrimination of UC-DAI from the associated 
UC-I tissues reached 89% sensitivity and 95% specificity, with an accuracy of 92%. Of note, we 
could not observe any statistical difference regarding the number of false positive or false negative 














































































































The diagnosis of colitis-associated dysplasia and especially of low-grade dysplasia based on H&E 
stained section remains difficult as a significant degree of inter-observer variability has been 
demonstrated even between expert GI pathologists.30 Hence, confirmation of the diagnosis by a 
second pathologist is recommended.12,31 These evidences support the need for histological markers to 
facilitate the diagnosis of dysplasia. In this context Hence, our proteomic pilot study revealed for the 
first time a differential distribution of SLC12A2 in colorectal dysplasia compared to inflammatory 
and normal colonic tissues originating from the same UC patients. This was further confirmed by 
IHC, with SLC12A2 showing a specific loss of gradient staining pattern in colitis-associated dysplasia 
and cancer. The interobserver OA for SLC12A2 pattern assessment in UC-DAI lesions reached 
95.24% with multirater κfree of 0.90 (IC95%: 0.78 – 1.00) almost perfect agreement and was able to 
discriminate UC-DAI from their associated UC-I tissues with 89% sensitivity and 95% specificity, 
with an accuracy of 92% with high sensitivity, specificity and accuracy. Furthermore, for In non-UC 
patients, SLC12A2 staining pattern was also able to discriminate conventional colorectal adenomas 
and cancers at any pT stages from normal colonic tissues.  
SLC12A2, is also known as Na+, K+, 2Cl- cotransporter 1 (NKCC1) or as Bumetanide-sensitive 
sodium-(potassium)-chloride cotransporter 2 (BSC2), and is a sodium, potassium and chloride 
electroneutral co-transporter across the plasma membrane. SLC12A2 is expressed in many cell types 
including polarised secretory epithelia such as lacrimal glands and intestine, and is implicated in fluid 
secretion.32–35 There are two isoforms of SLC12A2 resulting from an alternative splicing of exon 2136 
and sharing 98.68% of identity. Taken the sequences of the unique peptides observed in our proteomic 
results and the specificity of the antibody used for IHC, both variants could be upregulated in 
precancerous and cancerous colorectal lesions. Their potential posttranslational modifications are 
possible despite not observed in our data.37,38 However, in the CRC cell line HT29, the long transcript 
variant of SLC12A2 was found 14.9 times more abundant then the short form.39 A specific study 
should address these aspects using appropriate technology to decipher the potential role of SLC12A2 
variants in the colorectal cancer pathophysiology using statistically relevant number of individual 
human samples. 
To our knowledge, differential proteomics in UC neoplastic progression has been addressed in two 
previous studies aiming at identifying markers to predict and detect UC-associated dysplasia/cancer 
and to highlight biological processes involved in CAC progression.40,41 Brentnall T. et al. applied an 
iTRAQ-based quantitative proteomic analysis of epithelial cells isolated by 
ethylenediaminetetraacetic acid (EDTA) shake-off from 5 fresh frozen colonic tissues where 
highlighted 98 proteins differentially distributed between non dysplastic tissues from UC-patients and 
normal tissues from non IBD-controls, of which only 4 of these proteins (encoded by S100A6, P4HB, 
PDIA3 and FCGBP) were also found differentially distributed significant in our dataset. May D. et al. 
used a label-free quantitative proteomic analysis of epithelial cells isolated by EDTA shake-off from 5 
fresh frozen colonic tissues where identified 273 proteins were differentially distributed between non-
dysplastic tissues from UC patients with and without dysplasia. Only 17 were also found differentially 
distributed in our dataset, with 3 proteins upregulated in our study (encoded by CLCA1, CYCS and 
CLTC genes) while downregulated in May et al. The authors only provided the lists of proteins with 
ratio (≤ 0.5 or ≥ 2.0) with no raw data accessible in public repository, making impossible the 
comparison of SLC12A2 and other significant proteins distributions between studies. Only few of 
these significant proteins were also found in our study. Obvious differences in techniques and strategy 
including nature of samples (FFPE vs. fresh frozen) and experimental instrument systems might 













































































































cells with 10% of remaining cells likely contributing to background signal. CAC arises from early 
dysplastic lesions located in small tissue areas, hence the LCM technique applied in our work was 
well adapted to collect limited samples in such restricted regions22, LCM indeed also increases sample 
homogeneity, avoids lamina propria cells collection and enriched sample with epithelial cells of 
interest, while limiting the impact of neighbouring tissues and therefore background signal.38 This was 
further supported by our IHC results, as no SLC12A2 staining was observed in the lamina propria, 
suggesting that the SLC12A2 upregulation detected by proteomics might have been due to a high 
purity in epithelial cells content in our FFPE treated samples, limiting strongly contaminations of non-
epithelial cells. But more importantly the clinical questions addressed in both previous works were 
different from the one of our study. They aimed These authors aimed at highlighting proteins able to 
identify UC-patients at high risk of colorectal dysplasia or cancer and compared proteomes of 
unpaired colorectal tissues originating from UC patients with and without dysplasia., whereas our 
purpose was to identify proteins that were able to discriminate colorectal dysplastic lesions from 
chronic inflammatory mucosa taken from the same patient. As CAC arises from early dysplastic 
lesions located in small tissue areas, the LCM applied in our work was well adapted to collect such 
restricted regions22, increasing sample homogeneity by enrichment with epithelial cells.42  
Our proteomic results were confirmed by IHC including 28 UC-DAI cases with paired inflammatory 
and normal colorectal tissues, in which most were low-grade UC-DAI. Early markers to differentiate 
low-grade UC-DAI from UC-I are the most relevant and considered as a priority for UC patients 
cancer surveillance, as emphasis by Cremer A. et al. in a Belgian national cohort study, where more 
DAI patients developed high-grade colorectal dysplasia or cancer (9% and 27% respectively) during 
their follow-up compared to DSp patients (3% and 11% respectively).14,41,42   
The low number of patients that could be selected for the proteomic study (n=5) and mainly due to 
technical and design constraints (retrospective FFPE reviewing, 5000 epithelial cells par tissue 
requirement and paired design) for some patients remains a limitation. However, our paired tissues 
design overcomes the inter-subject variability allowing higher statistical power achievement than the 
analysis of unpaired tissues.43,44 The patient number is improved in the IHC study (n=28 UC-DAI 
cases with paired inflammatory and normal colorectal tissues), focusing on low-grade UC-DAI.  
Indeed early markers differentiating low-grade UC-DAI from UC-I are the most relevant ones and 
considered as a priority for UC patients cancer surveillance, as emphasis by Cremer A. et al. based on 
a Belgian national cohort study, where more DAI patients developed high-grade colorectal dysplasia 
or cancer (9% and 27% respectively) during their follow-up compared to DSp patients (3% and 11% 
respectively).14,45,46   
In a recent study analysing the transcriptomic changes in patients with longstanding UC to reveal 
CAC pathways, SLC12A2 was not found differentially expressed between short- and longstanding 
UC A transcriptomic study analysing the samples from patients with UC to reveal CAC pathways 
could not find SLC12A2 as differentially expressed between short- and long-standing UC.47 These 
data and our results suggest that SLC12A2 upregulation/perturbation does not appear in longstanding 
UC, but could be specific of inflammation-dysplasia-carcinoma progression as early as low grade 
dysplasia, as observed in our human (including lesions up to pT4NM CAC stages) and AOM/DSS 
mice model samples.  
In line with our results, Zhang Y et al. who analysed 20 fresh-frozen CRC tissues by LCM and label 
free proteomics identified SLC12A2 as one of the 67 proteins upregulated in CRC (3 times more 
abundant in CRC than in normal paired tissues).44 This is consistent with our observation in non-IBD 













































































































proteomics, with SLC12A2 being 2 times more abundant in pT1-pT2 CRC compared to normal 
colorectal tissues.26 In the present work, we demonstrated a differential distribution of SLC12A2 IHC 
staining specific pattern in dysplastic and neoplastic colorectal lesions in the UC-context, but also in 
precancerous and cancerous non-IBD colorectal lesions. Altogether, this suggests that SLC12A2 
perturbation and upregulation leading to a loss of gradient of expression along the crypts, could be 
associated to both UC and non-UC colorectal cancer.   
In line with our results, Zhang Y et al. found SLC12A2 upregulated in CRC48 which is consistent with 
a previous work of our team were SLC12A2 was found 2 times more abundant in pT1-pT2 CRC 
compared to normal colorectal tissues.26 Our proteomic and IHC results for SLC12A2 IHC staining 
pattern in dysplastic and neoplastic colorectal lesions in UC and non-IBD individuals altogether 
suggest that SLC12A2 perturbation and upregulation leading to a loss of gradient of expression along 
the crypts, might be associated to both UC and non-UC colorectal cancer progression.  
Despite efforts made to identify new histological markers for the diagnosis of colitis-associated 
dysplasia To our knowledge none of the proteins identified to date and proposed as histological 
diagnosis marker of colitis-associated dysplasia has been recommended in guidelines, consensus, 
implemented in routine histological evaluation or included in any prospective evaluation trial.15,49–51 
Ki67, albeit upregulated in colitis-associated dysplasia52, Ki67 has been  was shown to be already 
upregulated in non-dysplastic colon of UC-patients with dysplasia, limiting therefore its use for the 
distinction of DAI from inflammation.53 Moreover, it was shown that the percentage of Ki67 positive 
cells percentage was reported as already significantly higher in active and inactive UC compared to 
normal subject mucosa. Consistently we showed a slight but ot significant increased percentage of 
Ki67 positive cells in UC-I and UC-DAI compared to UC-N. Unlike SLC12A2, Ki67 staining was not 
able to discriminate colorectal dysplasia from chronic colonic inflammation originating from the same 
patients, suggesting that SLC12A2’s pattern is more efficient than the Ki67 for the discrimination of 
UC-associated dysplasia. The cellular tumour antigen p53 overexpression has been suggested for 
dysplasia-associated to UC detection54, but the ECCO and the ESP jointly emphasised that 
regenerative epithelium may also show p53 overexpression, limiting therefore its suitability when 
considered alone as a histological marker.15 Detection of p53 has been suggested in combination with 
AMACR using a hybrid scoring system based on the semi-quantitative intensity scale and the 
percentage of positive cells.50 Such  semi-quantitative assessment can be less reproducible due to 
inter-observer lower agreement; while the count of positive cells remains rather time consuming for 
routine analysis if not automated. We obtained preliminary interesting results on the potential added 
value of p53 in our cases showing false positive or false negative results with SLC12A2 (n=6, data 
not shown). Another dedicated study should be performed to check for any significant added value of 
the combined assessment of p53 and SLC12A2.  
In our study, SLC12A2 staining pattern appeared more relevant than its staining intensity with a 
substantial to almost perfect inter-observer agreement. This simple criterion was able to clearly 
delimit dysplastic from non-dysplastic crypts. Few evidences in the literature might explain the 
specific this particular loss of gradient pattern in preneoplastic and neoplastic colorectal tissues. 
SLC12A2 has been described as a stem cell marker in the small intestine55. SLC12A2 expression is 
restricted to the bottom of the crypts, consistent with the staining observed in our normal and 
inflammatory colorectal tissues., with its expression restricted to the bottom of the crypts consistent 
with the staining observed in normal and inflammatory colorectal tissues. A hypothesis could be that 
the expression of SLC12A2 in upper portions of the crypts, including surface epithelia, in dysplastic 
and cancerous tissues, reflects an onset of cancer stem cells, known to be involved in carcinogenesis 













































































































conventional adenomas to pT2 and of lower abundance in later CRC stages (pT3 and pT4), SLC12A2 
increase is maintained in advanced pT3 and pT4, suggesting other roles or fate for this protein in 
cancer progression and likely in the colorectal cancer pathophysiology. But unlike the stem cell 
protein Olfactomedin-4 found increased from conventional adenomas to pT2 and of lower abundance 
in later CRC stages (pT3-4), the increase in SLC12A2 is maintained in advanced pT3-4, suggesting 
other roles or fates for this protein in colorectal cancer pathophysiology.26 Ion channels are known to 
play crucial roles in cell proliferation, differentiation, apoptosis and motility and their dysfunctions 
could lead to hallmarks of cancer.58 SLC12A2 has already been studied in other cancers such as 
glioma, glioblastoma, lung, pancreatic, hepatocellular, oesophageal and gastric cancers, with 
suggested roles in epithelial-to mesenchymal transition process, cytoskeleton modulation, EGFR 
kinase inhibitor resistance and G1/S and G2/M cell cycle progression.59–65 However, the role of 
SLC12A2 in dysplastic or neoplastic colorectal transformation and especially in inflammation-
associated neoplastic colorectal transformation remains to be elucidated and is beyond the scope of 
this paper, as well as the role of other proteins highlighted in our proteomic study, for which genomic 
or proteomic data exist. However, the role of SLC12A2 (its variants, potential posttranslational 
modifications, as any other proteins found differentially distributed by proteomics and for which other 
evidences exist66–69) in relation to the dysplastic or neoplastic colorectal transformation and especially 
in inflammation-associated neoplastic colorectal transformation remains to be elucidated and is 
beyond the scope of this paper. 
In conclusion, despite that further studies are warranted to validate SLC12A2 as a clinically useful 
marker, our results propose SLC12A2 as a promising histological marker for colorectal cancer and 
dysplasia identification. Here, we showed a specific immunohistochemical SLC12A2 IHC staining 
pattern in precancerous and cancerous colorectal lesions in the sporadic context and more importantly 
in ulcerative colitis UC, where no marker can reliably discriminate inflammation from dysplasia. The 
SLC12A2 loss of gradient pattern could be an easy IHC parameter that might open new perspectives 
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Figure 1. SLC12A2 immunohistochemistry results in AOM/DSS mouse colorectal tissues 
 (A) Illustration of the staining pattern frequency distribution among lesion types. (B) Distribution of 
staining intensity score results in each lesion type. The relevant p values are represented with * ≥ 
0.01, ** ≥ 0.001, *** ≥ 0.0001 and **** < 0.0001. PBS, normal tissue; I, inflammatory tissue; LGD, 
low-grade dysplasia; I-LGD, inflammatory tissues associated to LGD; HGD, high-grade dysplasia; I-
HGD inflammatory tissues associated to HGD; ADC, adenocarcinoma; I-ADC, inflammatory tissues 
associated to ADC. 
Figure 2. SLC12A2 immunohistochemistry in UC-DAI colorectal tissues 
(A) Illustration of the staining pattern frequency distribution among lesion types. (B) Distribution of 
staining intensity score results in each lesion type. (C) Representative pictures of SLC12A2 IHC 
staining in UC-N (1), UC-I (2) and UC-DAI (3). Pictures (4), (5) and (6) represent zones in dysplasia, 
inflammation and at the border of inflammatory and dysplastic areas respectively. The red dotted line 
in picture (3) separates the dysplastic (right) and the inflammatory (left) tissues. Arrows in picture (4) 
represent two normal crypts surrounded by dysplastic tissues. Picture (7) represents the negative 
control. Only significant p values are represented with * ≥ 0.01, ** ≥ 0.001, *** ≥ 0.0001 and **** < 
0.0001. UC-N, normal tissues from UC-DAI patients; UC-I, inflammatory tissues from UC-DAI 
patients; UC-DAI, dysplasia associated to UC inflammation. 
Figure 3. SLC12A2 immunohistochemistry results in UC-DSp colorectal tissues  
(A) Illustration of the staining pattern frequency distribution among lesion types. (B) Distribution of 
staining intensity score results in each lesion type. (C) Representative pictures of SLC12A2 IHC 
staining in UC-N (1) and UC-DSp (2). Only significant p values are represented with * ≥ 0.01, ** ≥ 
0.001, *** ≥ 0.0001 and **** < 0.0001. UC-N, normal tissues of UC-DSp patients; UC-DSp, 
dysplasia developed on UC inflammation-free mucosa. 
Figure 4. SLC12A2 immunohistochemistry results in UC-CAC colorectal tissues   
(A) Illustration of the staining pattern frequency distribution among lesion types. (B) Distribution of 
staining intensity score results in each lesion type. (C) Representative pictures of SLC12A2 IHC 
staining in UC-N (1), UC-I (2) and UC-CAC (3). Only significant p values are represented with * ≥ 
0.01, ** ≥ 0.001, *** ≥ 0.0001 and **** < 0.0001. UC-N, normal tissue of UC-CAC patient; UC-I, 
inflammatory tissue of UC-CAC patient; UC-CAC; colitis-associated cancer. 
Figure 5. Immunohistochemistry results in longstanding UC showing frequency distribution of 
SLC12A2 the staining patterns 
(A) Normal and inflammatory tissues from dysplasia-free longstanding UC, UC-DAI, UC-DSp and 
UC-CAC patients are represented. (B) Representative pictures of SLC12A2 IHC staining in UC-N (1) 








































































































































































































































































































































































































































































































































































Table 3. Results of the differential proteomic analysis  
 
Legend: UC-N, normal tissues from UC-DAI patients; UC-I, inflammatory tissues from UC-DAI patients; UC-DAI, 
dysplasia associated to UC inflammation; UC-DAI only, protein only quantified in UC-DAI tissues; UC-N only, 
protein only quantified in UC-N tissues















































































































N, normal; I, inflammatory; DAI, dysplasia associated to UC inflammation; DSp, dysplasia developed 
on UC inflammation-free mucosa; CAC, colitis-associated cancer; Div-margin, normal tissue taken at 
surgical margin of diverticulitis; T3T4-margin, normal tissue taken at surgical margin of pT3 or pT4 
colorectal cancers; LGA, low-grade conventional adenoma; HGA, high-grade conventional adenoma; 
SSA/P, sessile serrated adenoma/polyp; TSA, traditional serrated adenoma; HPP, hyperplastic polyp; 
pT1 to pT4; colorectal cancer from pT1 to pT4 stages; pT1- to pT4-adjacent, normal tissue 
surrounding pT1 to pT4 colorectal cancers; pT1-pT4-margin, the normal tissue taken at surgical 
margin of pT1 to pT4 colorectal cancers; All UC-patients, all normal, inflammatory, precancerous and 
cancerous tissues from UC-DAI, UC-DSp, UC-CAC and longstanding UC patients; All non-IBD 
precancerous and cancerous tissues, all LGA, HGA, SSA/P, TSA, HPP, pT1, pT2, pT3 and pT4 
tissues from non-IBD patients; All non-IBD precancerous and cancerous patients, all LGA, HGA, 













































































































Table 5. Sensitivity, specificity and accuracy of SLC12A2 staining pattern as criteria for tissue 
classifications  
 
N, normal; I, inflammatory; UC-DAI, dysplasia associated to UC inflammation; UC-CAC, UC-
associated cancer; LGA, low-grade conventional adenoma; HGA, high-grade conventional adenoma; 
Div-margin, normal tissue taken at surgical margin of diverticulitis; T3T4-margin, normal tissue taken 
at surgical margin of pT3 or pT4 colorectal cancers; pT1 to pT4; colorectal cancers from pT1 to pT4 
stages; pT-adjacent, the normal tissue surrounding pT1 to pT4 colorectal cancers; pT-margin, normal 
tissue taken at surgical margin of pT1 to pT4 colorectal cancers.  
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Figure 2C1 
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Figure 2C2 
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Figure 2C3 
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Figure 2C4 
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Figure 2C5 
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Figure 2C6 
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Figure 2C7 
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Figure 3C1 
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Figure 3C2 
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Figure 4C1 
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Figure 4C2 
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Figure 4C3 
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Figure 5B1 
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Figure 5B2 
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